Kimberly J. Popovits Sells 10,000 Shares of Genomic Health (GHDX) Stock

Genomic Health (NASDAQ:GHDX) CEO Kimberly J. Popovits sold 10,000 shares of the firm’s stock in a transaction dated Monday, May 14th. The shares were sold at an average price of $38.09, for a total transaction of $380,900.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Kimberly J. Popovits also recently made the following trade(s):

  • On Monday, April 16th, Kimberly J. Popovits sold 15,000 shares of Genomic Health stock. The shares were sold at an average price of $33.19, for a total transaction of $497,850.00.

GHDX stock opened at $38.24 on Friday. Genomic Health has a one year low of $37.99 and a one year high of $38.09. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of 237.31 and a beta of 0.62.

Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings data on Wednesday, May 2nd. The medical research company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.08. Genomic Health had a negative net margin of 1.95% and a positive return on equity of 3.15%. The company had revenue of $92.60 million during the quarter, compared to analyst estimates of $88.95 million. During the same period in the prior year, the firm earned ($0.02) earnings per share. The business’s quarterly revenue was up 12.5% on a year-over-year basis. equities research analysts predict that Genomic Health will post 0.45 EPS for the current fiscal year.

Several research firms have recently weighed in on GHDX. BidaskClub upgraded shares of Genomic Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 12th. ValuEngine upgraded shares of Genomic Health from a “hold” rating to a “buy” rating in a research report on Friday, May 11th. Zacks Investment Research upgraded shares of Genomic Health from a “hold” rating to a “strong-buy” rating and set a $42.00 price objective for the company in a research report on Wednesday, May 9th. Deutsche Bank raised their price objective on shares of Genomic Health from $32.00 to $34.00 and gave the company a “hold” rating in a research report on Thursday, May 3rd. Finally, Piper Jaffray restated a “hold” rating and set a $33.00 price objective on shares of Genomic Health in a research report on Thursday, March 8th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, two have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $34.00.

Hedge funds have recently bought and sold shares of the business. Meeder Asset Management Inc. lifted its stake in Genomic Health by 120.7% during the fourth quarter. Meeder Asset Management Inc. now owns 2,960 shares of the medical research company’s stock valued at $101,000 after buying an additional 1,619 shares in the last quarter. Teacher Retirement System of Texas purchased a new stake in shares of Genomic Health in the fourth quarter worth approximately $242,000. Virtu Financial LLC purchased a new stake in shares of Genomic Health in the fourth quarter worth approximately $261,000. Guggenheim Capital LLC purchased a new stake in shares of Genomic Health in the first quarter worth approximately $264,000. Finally, MetLife Investment Advisors LLC purchased a new stake in shares of Genomic Health in the fourth quarter worth approximately $301,000. 87.75% of the stock is owned by institutional investors.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply